Non Alcoholic Steatohepatitis Clinical Trials

17 recruitingLast updated: June 18, 2026

There are 17 actively recruiting non alcoholic steatohepatitis clinical trials across 10 countries. Studies span Not Applicable, Phase 2, Phase 1. Top locations include Boston, Massachusetts, United States, Beijing, Beijing Municipality, China, Baoding, Hebei, China. Updated daily from ClinicalTrials.gov.


Non Alcoholic Steatohepatitis Trials at a Glance

17 actively recruiting trials for non alcoholic steatohepatitis are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Boston, Beijing, and Baoding. Lead sponsors running non alcoholic steatohepatitis studies include Institut National de la Santé Et de la Recherche Médicale, France, Cambridge University Hospitals NHS Foundation Trust, and Brigham and Women's Hospital.

Browse non alcoholic steatohepatitis trials by phase

Treatments under study

About Non Alcoholic Steatohepatitis Clinical Trials

Looking for clinical trials for Non Alcoholic Steatohepatitis? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non Alcoholic Steatohepatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non Alcoholic Steatohepatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting

Identification of Liver Fibrosis Biomarkers

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisNon-alcoholic Fatty Liver
Roche Diagnostics GmbH575 enrolled2 locationsNCT06819917
Recruiting
Phase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)84 enrolled1 locationNCT03884075
Recruiting
Phase 1

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

Non Alcoholic Steatohepatitis
Sunshine Lake Pharma Co., Ltd.96 enrolled1 locationNCT07099118
Recruiting

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

Hepatocellular CarcinomaNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis+2 more
Institut National de la Santé Et de la Recherche Médicale, France710 enrolled1 locationNCT05623150
Recruiting

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

ObesityNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
Brigham and Women's Hospital150 enrolled2 locationsNCT05728697
Recruiting

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".

Liver CancerNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis+4 more
Institut National de la Santé Et de la Recherche Médicale, France800 enrolled1 locationNCT04690972
Recruiting

Integrated Diagnostics for Early Diagnosis of Liver Disease

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisAlcoholic Liver Disease+1 more
Manchester University NHS Foundation Trust1,200 enrolled1 locationNCT04666402
Recruiting
Not Applicable

The Olmsted NAFLD Epidemiology Study (TONES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
Mayo Clinic800 enrolled1 locationNCT04365855
Recruiting
Not Applicable

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Insulin Sensitivity/ResistanceObesityInsulin Resistance+16 more
Pichamol Jirapinyo, MD, MPH132 enrolled2 locationsNCT06138821
Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Lung CancerCancer RiskCancer Predisposition Syndrome+28 more
Dana-Farber Cancer Institute5,000 enrolled1 locationNCT05463796
Recruiting
Not Applicable

Prognostic Significance of Fatty Liver Disease in Bariatric Patients

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisObesity, Morbid+1 more
Esbjerg Hospital - University Hospital of Southern Denmark1,200 enrolled1 locationNCT03535142
Recruiting
Phase 1

A Study of INI-822 in Healthy Volunteers and Participants with Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Non Alcoholic Steatohepatitis
Inipharm Australia Pty Ltd104 enrolled7 locationsNCT05945537
Recruiting
Phase 2

Soluble Fibre Supplementation in NAFLD

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisHepatic Steatosis
McMaster University60 enrolled1 locationNCT05480696
Recruiting
Not Applicable

Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.

Non Alcoholic Steatohepatitis
Institute of Liver and Biliary Sciences, India72 enrolled1 locationNCT06676813
Recruiting
Phase 2

Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis

Intestinal microbiomeNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis+6 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)48 enrolled1 locationNCT05821010
Recruiting
Phase 2

Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.120 enrolled53 locationsNCT06569524
Recruiting

European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisNon-alcoholic Fatty Liver
Cambridge University Hospitals NHS Foundation Trust2,000 enrolled3 locationsNCT04190849